

Siglec-15

Catalog # PVGS1621

Product Information

Primary Accession Species	Q6ZMC9 Human
Sequence	Phe20-Thr263
Purity	> 90% as analyzed by SDS-PAGE
Endotoxin Level Biological Activity	Immobilized Anti-Siglec15 at 1.0 μ g/ml (100 μ l/well) can bind Siglec-15, hFc, Human with a EC_{50} = 5.184 ng/ml and a linear range of 0.064 \pm 200.0 ng/ml when detected by Mouse Anti-Human IgG Fc-HRP.
Expression System	HEK 293
Formulation Reconstitution	Lyophilized from a 0.2 μ m filtered solution in PBS. It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O or PBS up to 100 μ g/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Additional Information

Gene ID	284266
Other Names	Sialic acid-binding Ig-like lectin 15, Siglec-15, CD33 antigen-like 3, SIGLEC15, CD33L3
Target Background	Siglec-15 preferentially recognizes the Neu5Acalpha2-6GalNAcalpha-structure. Siglec-15 associates with the activating adaptor proteins DNAX activation protein (DAP)12 and DAP10 via its lysine residue in the transmembrane domain. Siglec-15 is the second human Siglec identified to have an activating signaling potential; unlike Siglec-14, however, it does not have an inhibitory counterpart.

Protein Information

Name	SIGLEC15
-------------	----------

Synonyms	CD33L3
Function	Binds sialylated glycoproteins.
Cellular Location	Membrane; Single-pass type I membrane protein.
Tissue Location	Expressed in macrophage and/or dendritic cells of spleen and lymph nodes

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.